Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?

CONCLUSION: The present study showed that CapTem regimen and regoafenib as third-line setting had similar activity in mCRC. We consider that CapTem regimen might be an alternative treatment option to regorafenib after two lines of chemotherapy in mCRC. However, prospective randomized trials with large number of patients are needed in this issue. PMID: 31983117 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research